9404results about How to "High output" patented technology

A method is provided for treating a subject, including applying a current to a site of the subject selected from the list consisting of: a vagus nerve of the subject, an epicardial fat pad of the subject, a pulmonary vein of the subject, a carotid artery of the subject, a carotid sinus of the subject, a vena cava vein of the subject, and an internal jugular vein of the subject. The method also includes configuring the current so as to treat a condition of the subject selected from the list consisting of: an autoimmune disease, an autoimmune inflammatory disease, multiple sclerosis, encephalitis, myelitis, immune-mediated neuropathy, myositis, dermatomyositis, polymyositis, inclusion body myositis, inflammatory demyelinating polyradiculoneuropathy, Guillain Barre syndrome, myasthenia gravis, inflammation of the nervous system, inflammatory bowel disease, Crohn's disease, ulcerative colitis, SLE (systemic lupus erythematosus), rheumatoid arthritis, vasculitis, polyarteritis nodosa, Sjogren syndrome, mixed connective tissue disease, glomerulonephritis, thyroid autoimmune disease, sepsis, meningitis, a bacterial infection, a viral infection, a fungal infection, sarcoidosis, hepatitis, and portal vein hypertension.

A method for the treatment of obesity or other disorders by electrical activation or inhibition of nerves is disclosed. This activation or inhibition can be accomplished by stimulating a nerve using an electrode. Dynamic stimulation through ramped cycling of electrical stimulation, stimulation frequency alteration, and/or duty cycle variance can produce therapeutic benefits.

An implantable cardiac stimulation device comprises a metabolic demand sensor, an activity sensor, and one or more pulse generators. The metabolic demand sensor and activity sensor can sense metabolic demand and physical activity parameters, respectively. The pulse generators can generate cardiac pacing pulses with timing based on a comparison of the metabolic demand and physical activity parameters. The timed cardiac pacing pulses can prevent a sleep apnea condition.

The above-described methods and apparatus are believed to be of particular benefit for patients suffering heart failure including cardiac dysfunction, chronic HF, and the like and all variants as described herein and including those known to those of skill in the art to which the invention is directed. It will understood that the present invention offers the possibility of monitoring and therapy of a wide variety of acute and chronic cardiac dysfunctions. The current invention provides systems and methods for delivering therapy for cardiac hemodynamic dysfunction.

Systems, methods and devices are provided for treating heart failure patients suffering from various levels of heart dilation. Heart dilation treated by reshaping the heart anatomy with the use of magnetic forces. Such reshaping changes the geometry of portions of the heart, particularly the right or left ventricles, to increase contractibility of the ventricles thereby increasing the stroke volume which in turn increases the cardiac output of the heart. The magnetic forces are applied with the use of one or more magnetic elements which are implanted within the heart tissue or attached externally and/or internally to a surface of the heart. The various charges of the magnetic forces interact causing the associated heart tissue areas to readjust position, such as to decrease the width of the ventricles. Such repositioning is maintained over time by the force of the magnetic elements, allowing the damaging effects of heart dilation to slow in progression or reverse.

An implantable stimulator and monitor measures a group of heart failure parameters indicative of the state of heart failure employing EGM signals, measures of blood pressure including absolute pressure P, developed pressure (DP=systolic P-diastolic P), and/or dP/dt, and measures of heart chamber volume (V) over one or more cardiac cycles. These parameters include: (1) relaxation or contraction time constant tau (.tau.); (2) mechanical restitution (MR), i.e., the mechanical response of a heart chamber to premature stimuli applied to the heart chamber; (3) recirculation fraction (RF), i.e., the rate of decay of PESP effects over a series of heart cycles; and (4) end systolic elastance (E.sub.ES), i.e., the ratios of end systolic blood pressure P to volume V. These heart failure parameters are determined periodically regardless of patient posture and activity level. The physician can determine whether a particular therapy is appropriate, prescribe the therapy for a period of time while again accumulating the stored patient data for a later review and assessment to determine whether the applied therapy is beneficial or not, thereby enabling periodic changes in therapy, if appropriate. Drug therapies and electrical stimulation therapies, including PESP stimulation, and pacing therapies including single chamber, dual chamber and multi-chamber (bi-atrial and/or bi-ventricular) pacing can be delivered. In patient's prone to malignant tachyarrhythmias, the assessment of heart failure state can be taken into account in setting parameters of detection or classification of tachyarrhythmias and the therapies that are delivered.

Haptic feedback interface devices using electroactive polymer (EAP) actuators to provide haptic sensations and/or sensing capabilities. A haptic feedback interface device is in communication with a host computer and includes a sensor device that detects the manipulation of the interface device by the user and an electroactive polymer actuator responsive to input signals and operative to output a force to the user caused by motion of the actuator. The output force provides a haptic sensation to the user. Various embodiments of interface devices employing EAP actuators are described, including embodiments providing direct forces, inertial forces, and braking forces.

Embodiments of the present disclosure includes a portable pulse oximeter, such as a handheld pulse oximeter, that provides a user with intuitive key navigation for device operation, which reduces an amount of visual concentration needed to handle and operate the oximeter. In various embodiments, the portable pulse oximeter includes one or more of user input keys disposed along curve, an alignment edge providing guidance by feel of a user's digits to the input keys, raised convex keys also providing navigation by feel, a protective boot disposed around various portions of the oximeter housing to protect against impacts, a table-top stand, combinations of the same, or the like.

An optimized Yb: doped fiber mode-locked oscillator and fiber amplifier system for seeding Nd: or Yb: doped regenerative amplifiers. The pulses are generated in the Yb: or Nd: doped fiber mode-locked oscillator, and may undergo spectral narrowing or broadening, wavelength converting, temporal pulse compression or stretching, pulse attenuation and/or lowering the repetition rate of the pulse train. The conditioned pulses are subsequently coupled into an Yb: or Nd: fiber amplifier. The amplified pulses are stretched before amplification in the regenerative amplifier that is based on an Nd: or Yb: doped solid-state laser material, and then recompressed for output.

A method of generating energy in a power plant (30) having a gas turbine (29), includes a first step a gas containing air (1) is compressed in a first compressor (2) of the gas turbine (29), a second step the compressed gas (3, 3a, 3b; 5; 7a, 7b) is fed to a combustion process with the addition of fuel (8) in a combustor (23), a third step the hot flue gas (9) from the combustor (23) is expanded in an expander or a turbine (10), driving a generator (18), of the gas turbine (29) while performing work, and a fourth step a partial flow of the expanded flue gas (11) is recirculated to the inlet of the first compressor (2) and admixed with the gas containing air (1). Carbon dioxide (CO₂) is separated from the compressed gas (3, 3a, 3b; 5; 7a, 7b) in a CO₂ separator (6) before the third step. In such a method, the overall size and energy costs are reduced by virtue of the fact that, to permit increased CO₂ concentrations in the CO₂ separator (6), not more than about 70% of the carbon dioxide contained in the compressed gas (3, 3a, 3b; 5, 5a, 5b; 7a, 7b) is removed from the compressed gas (3, 3a, 3b; 5, 5a, 5b; 7a, 7b).

Devices and methods for treating degenerative, congestive heart disease and related dysfunction are described. Passive and active cardiac support structures mitigate changes in ventricular structure (i.e., remodeling) and deterioration of global left ventricular performance related to tissue damage precipitating from ischemia, acute myocardial infarction (AMI) or other abnormalities. Cardiac efficiency is improved by providing reinforcement that restores or maintains an elliptical ventricular shape and mimics the position and positive inotropic effects of helical wound myofibrils to provide active contraction of the ventricle in synchrony with the metabolically required cardiac pace or output. In addition, the cardiac support structures compensate or provide therapeutic treatment for congestive heart failure and/or reverse the remodeling that produces an enlarged heart. The structures may be implanted in target heart regions using less invasive surgical techniques, such as those involving port access or small incisions into the thoracic cavity.

The present invention relates to monitoring septal wall motion of the atrial and/or ventricular chambers of a heart for optimizing cardiac pacing intervals based on signals derived from said wall motion. At least one lead of medical device is equipped with a motion sensor adapted to couple to septal tissue. The device receives and may post-process (e.g., suitably filter, rectify and/or integrate) motion signals to determine acceleration, velocity or displacement. During pacing interval optimization the wall motion is measured for many pacing intervals and the pacing interval setting(s) that produce minimal wall motion are implemented for therapy delivery. In addition, the present invention provides methods for periodically determining whether to cease or resume delivery of a bi-ventricular pacing therapy to a patient that may have experienced beneficial reverse remodeling of the heart.

A power generator according to the present invention includes: a power generating section (101) for outputting DC energy; an oscillator (103) for converting the DC energy into RF energy having a frequency f0; a first antenna (107) for transmitting the RF energy; a second antenna, which receives, by coupling a resonant magnetic field, at least a part of the RF energy transmitted by the first antenna (107); and an output converting section (120) for converting the RF energy supplied from the second antenna (109) into AC energy having a lower frequency than the RF energy. If the oscillator (103) has a voltage step-up ratio Voc, the output converting section (120) has a voltage step-up ratio Vtr, the first inductor (107a) of the first antenna (107) has an inductance L1, the second inductor (109a) of the second antenna (109) has an inductance L2, and the first and second antennas (107, 109) have a coupling coefficient k, the power generator satisfies (L2/L1)≧(k/(Voc×Vtr))².

In order to construct an integrated storage system by reinforcing collaboration of components or functions of a storage system in which a storage area network (SAN) is used, in a computer system having multiple client computers, multiple various servers, multiple various storages which keep data, and a local area network (LAN) which connects the computers and the servers, a storage area network (SAN) which lies between the servers and storages forms a switched circuit network which is capable of connecting any server and any storage through fiber channel FC switches. The computer system further includes a terminal which is equipped with operation and management software which performs storage management including management of logical volumes in the various storages, data arrangement, error monitoring, management of setting up the FC switches, and backup for data in the storages.

The present invention relates to a method and apparatus for monitoring haemodynamic function in animals and humans during anaesthesia and surgery. During anaesthesia and surgery the subject's haemodynamic, respiratory, neuromuscular and neurological functions are monitored as indicators of the condition of the health of the subject. Commonly, variations in blood pressure are used to imply corresponding variations in cardiac output, i.e. good blood pressure equals good cardiac output. The present invention utilizes a device to monitor changes of blood flow in peripheral blood vessels of the subject as an indicator of cardiac output. This is believed to provide a much more accurate indicator.

The invention relates to systems and methods for rapidly and isothermally expanding and compressing gas in energy storage and recovery systems that use open-air hydraulic-pneumatic cylinder assemblies, such as an accumulator and an intensifier in communication with a high-pressure gas storage reservoir on a gas-side of the circuits and a combination fluid motor/pump, coupled to a combination electric generator/motor on the fluid side of the circuits. The systems use heat transfer subsystems in communication with at least one of the cylinder assemblies or reservoir to thermally condition the gas being expanded or compressed.

The ultrasound therapeutic system of the present invention generally includes a generator unit, at least one transducer treatment head, and a programmable controller. The generator is in operable communication with the at least one transducer treatment head such that electric power outputted from the generator to the head is converted into acoustic power by the head. Re-programmable software at the controller generally controls all features and functions for the system. In particular, the controller calculates an initial optimal treatment dose, maintains effective acoustic power transmitted to the patient through the at least one treatment head, performs calibration procedures for the at least one treatment head, controls outputting for each supported treatment mode, and provides for various other features and functions.

A control system simultaneously controls a multi-zone process with a self-adaptive model predictive controller (MPC), such as temperature control within a plastic injection molding system. The controller is initialized with basic system information. A pre-identification procedure determines a suggested system sampling rate, delays or “dead times” for each zone and initial system model matrix coefficients necessary for operation of the control predictions. The recursive least squares based system model update, control variable predictions and calculations of the control horizon values are preferably executed in real time by using matrix calculation basic functions implemented and optimized for being used in a S7 environment by a Siemens PLC. The number of predictions and the horizon of the control steps required to achieve the setpoint are significantly high to achieve smooth and robust control. Several matrix calculations, including an inverse matrix procedure performed at each sample pulse and for each individual zone determine the MPC gain matrices needed to bring the system with minimum control effort and variations to the final setpoint. Corrective signals, based on the predictive model and the minimization criteria explained above, are issued to adjust system heating/cooling outputs at the next sample time occurrence, so as to bring the system to the desired set point. The process is repeated continuously at each sample pulse.

A device for regulating blood pressure between a patient's left atrium and right atrium comprises an hourglass-shaped stent comprising a neck region and first and second flared end regions, the neck region disposed between the first and second end regions and configured to engage the fossa ovalis of the patient's atrial septum; and a one-way tissue valve coupled to the first flared end region and configured to shunt blood from the left atrium to the right atrium when blood pressure in the left atrium exceeds blood pressure in the right atrium. The inventive devices may reduce left atrial pressure and left ventricular end diastolic pressure, and may increase cardiac output, increase ejection fraction, relieve pulmonary congestion, and lower pulmonary artery pressure, among other benefits. The inventive devices may be used, for example, to treat subjects having heart failure, pulmonary congestion, or myocardial infarction, among other pathologies.